Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine
- Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design
The agency accepts the invitation - A $150M gift enables City of Hope to establish $1M Stephenson Prize in pancreatic cancer research, build research program focused on the disease
- Group chairs propose funding strategy to jump-start correlative studies
- Karen Knudsen to leave ACS
- 2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS